June 2019

First FDA-Approved As-Needed Treatment for Acquired, Generalized Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women NDA Approval Triggers $60 Million Milestone Payment to Palatin Jun 21, 2019, 17:40 ET CRANBURY, N.J., June 21, 2019 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval …

FDA Approves New Drug Application for Vyleesi™ (bremelanotide injection) Read More »

PL-8177 is a Melanocortin Receptor 1 Agonist CRANBURY, N.J., June 6, 2019 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation …

Palatin Technologies Granted FDA Orphan Drug Designation — PL-8177 for the Treatment of Non-Infectious Uveitis Read More »